Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708637 · ClinicalTrials.gov registry record · Phase 4
Ocular Safety and Usability Study for FYB203 PFS
A Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Formycon.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06708637: Completed Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Formycon.
NCT06708637 is a Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema that has completed, run by Formycon. The registered enrollment target is 30 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708637, a Phase 4 study of Age-related Macular Degeneration and Diabetic Macular Edema, has completed, sponsored by Formycon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
Primary Outcome
To assess the ocular safety of the FYB203 PFS in terms of preparation and administration by Retina Specialists.
Conditions Studied
Interventions
- DRUG FYB203 2 mg (0.05 mL of 40 mg/mL)
Study Locations (4)
California
- Research Site - Campbell
- Research Site - Long Beach
- Research Site - Redlands
Oregon
- Research Site - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 4 |
What the finished NCT06708637 record still lists
NCT06708637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which FYB203 2 mg (0.05 mL of 40 mg/mL) is the first listed.
NCT06708637 reports a single indexed study location in California, Oregon.
Frequently Asked Questions
What is clinical trial NCT06708637 about?
NCT06708637 is a clinical study titled "Ocular Safety and Usability Study for FYB203 PFS". The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
What is the current status of trial NCT06708637?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-09-20. Estimated completion is 2024-10-08.
What conditions does trial NCT06708637 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion with Macular Edema.
What interventions are being tested in trial NCT06708637?
The interventions under investigation include: FYB203 2 mg (0.05 mL of 40 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT06708637?
This trial is sponsored by Formycon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708637 being conducted?
This trial has 4 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06708637's enrollment target sits among peer trials
30 59th of 74 higher than 15 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ocular Safety and Usability Study for FYB201 PFS
COMPLETED · Phase 4
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI